The fatigue resolved over time after cessation of therapy.Patients who received olaparib had small but statistically and clinically significant increases in nausea, vomiting, and appetite loss scores during treatment.[102][Level of evidence A3] Patients who received olaparib experienced statistically significant greater fatigue than patients who received placebo, but the differences did not meet the criteria for clinical significance.
The fatigue resolved over time after cessation of therapy.
Patients who received olaparib had small but statistically and clinically significant increases in nausea, vomiting, and appetite loss scores during treatment.[102][Level of evidence A3] TNBC is defined as the absence of staining for ER, PR, and HER2.